Keith Flaherty

Last updated

Keith Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. [1] He was previously a professor of medicine at the University of Pennsylvania. He is known for his research on targeted therapies for cancer, and in particular for his work on the melanoma drug vemurafenib. [2] [3] [4] [5] In 2013, Massachusetts General Hospital partnered with AstraZeneca to partner Flaherty's research into developing a formula to identify vulnerabilities of tumors with AstraZeneca's library of drugs. [6]

References

  1. Keith T. Flaherty, MD - Massachusetts General Hospital, Boston, MA
  2. Target Cancer - A Roller Coaster Chase for a Cure - Series - NYTimes.com
  3. Target Cancer - After Long Fight, Melanoma Drug Gives Sudden Reprieve - Series - NYTimes.com
  4. Target Cancer - A Drug Trial Cycle - Recovery, Relapse, Reinvention - Series - NYTimes.com
  5. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma — NEJM
  6. Weintraub, Karen (19 May 2013). "MGH, AstraZeneca partner to create new drug combos". Boston Globe. Retrieved 30 January 2015.